---
search:
  boost: 2 
---

# Antiparasitics

This is a subcategory of Topical Agents.

## Decision Tree

[Antiparasitics - NP - Eurax, Malathion, Sklice, Spinosad*](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?origin=OfficeDotCom&lang=en-US&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUN01CT1Q3WU9OUTlUMjYzUExKWDA1WFg1SCQlQCN0PWcu&topview=Preview)

## Formulary

### Preferred

| Preferred                       | Generic Name | Quantity | Time (Days) |
|:--------------------------------|:-------------|:--------:|:-----------:|
| Natroba <sup>BvG</sup>          |              |          |             |
| Permethrin                      |              |          |             |
| Piperonyl Butoxide / Pyrethrins |              |          |             |

### Non-Preferred

| Non-Preferred  | Generic Name | Quantity | Time (Days) |
|:---------------|:-------------|:--------:|:-----------:|
| Eurax          |              |          |             |
| Ivermectin Lot |              |          |             |
| Malathion      |              |          |             |
| Spinosad       |              |          |             |

## Authorizations 

**Length of Authorizations**: 14 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response to at least **14 days** with at least **one preferred** drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_Criteria%20_APPROVED.pdf#page=102)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_v7_Approved.pdf#page=32)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
